Predilife Stock

Predilife ROE

The Return on Equity (ROE) of Predilife (ALPRE.PA) as of Aug 7, 2026 is 99.92 %. In the previous year, Return on Equity (ROE) was 107.87 % — a change of -7.37% (lower).

ROE

99.92 %

YoY

-7.37%

Last updated:

In 2026, Predilife's return on equity (ROE) was 99.92 %, a -7.37% increase from the 107.87 % ROE in the previous year.

Access this data via the Eulerpool API

Predilife Stock analysis

What does Predilife do? Predilife SA is a company specializing in predictive medicine. It was founded in Switzerland in 2011 and has since been based in Marseille, France. The company currently has around 50 employees, most of whom are scientists and doctors. The idea for Predilife SA came from the realization that many diseases can be prevented if they are detected and treated in advance. As most diseases also have a genetic component, Predilife SA focuses on the development of tests that calculate individual disease risk based on individual genetics. The business model of Predilife SA is based on the development and sale of predictive genetic tests for various diseases. The company works with health insurance companies, insurance companies, companies, as well as directly with end customers. The company believes that predictive tests represent an opportunity for many people to detect diseases early and take appropriate preventive measures. The company offers predictive tests for a range of diseases, including cancer, cardiovascular diseases, neurodegenerative diseases, and diabetes. The tests are based on state-of-the-art molecular diagnostic methods that allow for the identification of genetic changes that increase individual disease risk. The tests are conducted in specialized laboratories and interpreted by qualified doctors and geneticists. Predilife SA operates four different divisions and offers a range of predictive tests for each division: Division 1: Cancer prevention This division focuses on tests for common types of cancer such as breast, colon, and prostate cancer. The tests assess the individual risk of developing cancer and help optimize prevention and surveillance measures. Division 2: Cardiovascular diseases This division offers tests that assess the individual risk of cardiovascular diseases such as heart attack or stroke. The results are used to take targeted preventive measures. Division 3: Neurological diseases This division develops tests for neurodegenerative diseases such as Alzheimer's or Parkinson's. The results help determine individual risk and take appropriate preventive measures. Division 4: Diabetes This division offers tests that assess the individual risk of type 2 diabetes. The results are used to take targeted preventive measures. In addition to predictive tests, Predilife SA operates its own research department that focuses on the development of new predictive tests and the further development of existing tests. The company collaborates with leading scientists and institutions worldwide. Overall, Predilife SA aims to make predictive medicine accessible to as many people as possible. The company relies on state-of-the-art technologies and high professional competence. Predilife is one of the most popular companies on Eulerpool.

ROE Details

Decoding Predilife's Return on Equity (ROE)

Predilife's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Predilife's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Predilife's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Predilife’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Predilife stock

Return on Equity (ROE) of Predilife is 99.92 % in 2026.

Return on Equity (ROE) of Predilife changed from 107.87 % to 99.92 %, representing a -7.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Predilife since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Predilife with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Predilife

All Key Metrics — Predilife